|
Total: $313.95M |
||||
|
Company |
Location |
Date |
Amt. (M) |
Details |
|
Amsterdam Molecular Therapeutics Holding NV |
Amsterdam, the Netherlands |
10/6 |
€15 ($20.75) |
Amsterdam raised $20.75M in an equity offering with Advent Venture Partners, Gilde Healthcare Partners, Credit Agricole Private Equity and Forbion Capital Partners |
|
aTyr Pharma Inc. |
San Diego |
10/26 |
$23 |
aTyr raised $23M in a Series C round led by Domain Associates and including Alta Partners, Polaris Venture Partners and Cardinal Partners |
|
Cerenis Therapeutics SA |
Toulouse, France |
10/22 |
$13.9 |
Cerenis raised $13.9M in a second close of its Series C led by IRDI-IXO; other investors were Strategic Investment Fund and all previous investors |
|
Convergence Ltd. |
Cambridge, UK |
10/5 |
$35.4 |
Convergence raised $35.4M after being spun out by GlaxoSmithKline plc; investors were Apposite Capital, New Leaf Venture and SV Life Sciences |
|
ContraFect Corp. |
New York |
10/27 |
$14.2 |
ContraFect closed a $2.2M Series A financing, led by Equity Source Partners LLC, and a $12M Series B financing, led by Maxim Group LLC |
|
Dicerna Therapeutics Inc. |
Watertown, Mass. |
10/22 |
$4 |
Dicerna raised $4M in a second closing of its Series B round, raising a total of $29M from existing investors Oxford Bioscience Partners, Skyline Ventures, Abingworth and Domain Associates and new investor SR One |
|
Dipexium Pharmaceuticals LLC |
New York |
10/20 |
$1.4 |
Dipexium raised $1.4M in an offering of its Class A Member Interests in a multiple-closing transaction starting July 23 |
|
Innovacell Biotechnologie AG |
Innsbruck, Austria |
10/7 |
€4.3 ($6) |
Innovacell received $6M through its shareholders |
|
Metabolic Solutions Development Co. |
Kalamazoo, Mich. |
10/22 |
$23.5 |
Metabolic Solutions raised $23.5M in a Series D round led by Hopen Life Sciences with support from Southwest Michigan First Life Science Fund |
|
Noxxon Pharma AG |
Berlin |
10/13 |
$2.8 |
Noxxon raised another €2M ($2.8M) in a Series D round, bringing the total raised to €35 |
|
Pathwork Diagnostics Inc. |
Redwood City, Calif. |
10/7 |
$30 |
Pathwork closed a $30M Series C financing led by Alta Partners, with participation from existing investors Abingworth, Advent Venture Partners, Novus Ventures, Propsect Venture Partners and Venrock |
|
Pearl Therapeutics Inc. |
Redwood City, Calif. |
10/19 |
$69 |
Pearl raised $69M in a Series C financing; investors were Vatera Healthcare Partners, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures |
|
Prolong Pharmaceuticals LLC |
South Plainfield, N.J. |
10/13 |
$30 |
Prolong secured $30M in funding from an undisclosed investor |
|
Regulus Therapeutics Inc. |
La Jolla, Calif. |
10/29 |
$10 |
Regulus received a $10M equity investment from partner Sanofi-Aventis Group SA as part of their microRNA-based drugs for fibrosis deal |
|
Synosia Therapeutics |
Basel, Switzerland |
10/13 |
$30 |
Synosia raised $30M in a third round with partner UCB leading the financing with a $20M investment; other investors were Versant Ventures, 5AM Ventures, Novo A/S, Aravis Venture, Investor Growth Capital and Swiss Helvetia Fund |
|
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. |
||||